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1. Introduction 
Irritable bowel syndrome (IBS) is a disease in which, typically, alterations in intestinal 
motility and visceral hypersensitivity appear to exist, apparently without any organic 
alteration (Thompson, 1991). Several pathogenic factors responsible for IBS have been 
suggested. It seems that there are cell factors, which give reason to believe that there is a 
low-grade intestinal inflammation in this pathology (Ortiz-Lucas et al., 2010). Several 
cytokines, such as tumour necrosis factor α (TNFα), interleukin 1, and interleukin 6, 
contribute to the pathogenesis (Ardizzone and Bianchi Porro, 2005; Pizarro et al., 2006). 
Macrophages are the major producers of TNFα, and, interestingly, they are also highly 
responsive to TNFα. TNFα has been shown to play a pivotal role in activating the cytokine 
cascade in many inflammatory diseases and it has been proposed as a therapeutic target for 
a number of diseases. Consequently, recent strategies for the treatment of intestinal 
inflammation have primarily targeted the immunopathogenic processes that mediate 
intestinal inflammation at the cytokine level (Bamias et al., 2003; Sandborm and Targan, 
2002). At present, pharmacotherapy represents the mainstay of inflammatory bowel disease 
management (Stein and Hanauer, 1999). Some anti-inflammatory or immuno-modulating 
drugs, including salicylates and methotrexate, are able to decrease intracellular 
adenosine 5´-triphosphate concentrations and raise extracellular adenosine levels. It has 
been proposed that such properties can significantly contribute to the drugs’ 
pharmacological actions in inflammatory diseases (Cronstein et al., 1999).  
Several lines of evidence suggest that adenosine regulates immunity and inflammation 
(Amann and Peskar, 2002; Montesinos et al., 2007). The wide distribution of adenosine 
receptors (AR) as well as enzymes for purine metabolism in different gut regions suggests a 
complex role for this mediator in the regulation of gastrointestinal functions (Antonioli et 
al., 2008). Adenosine binds to four different types of G protein-coupled cell surface receptors 
referred to as A1R, A2AR, A2BR, and A3R, each having a unique pharmacological profile, 
tissue distribution and signalling pathway (Jacobson and Gao, 2006). All known ARs 
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contribute to the modulation of inflammation, as demonstrated by many in vitro and in vivo 
pharmacological studies (Hasko and Cronstein, 2004; Montesinos and Constein, 2001). The 
involvement of adenosine pathways in the anti-inflammatory and immunomodulating 
effects becomes evident. These observations have stimulated the research of novel drugs 
suitable for treatment of intestinal inflammatory disorders through the pharmacological 
modulation of adenosine pathways (Cavalcante et al., 2006; Guzman et al., 2006; Odashima 
et al., 2005).  
One medication which is successfully used in functional dyspepsia and IBS is the fixed 
herbal combination product STW 5 (Iberogast®; Madisch et al., 2004; Perez and Youssef, 
2007; Raedsch et al., 2007; Schmulson, 2008). There is growing evidence that STW 5 besides 
being effective in functional dyspepsia, also improves IBS symptoms (Madisch et al., 2004; 
Krueger et al., 2009). STW 5 and its fresh plant component Iberis amara (STW 6) show a 
powerful reduction of morphological and contractile damages observed after experimental 
inflammation within the small intestine, and may thus have a promising therapeutic value 
as anti-inflammatory drug (Michael et al., 2009).  
We therefore investigated the effect of STW 5 and its main component STW 6 on 
experimentally induced inflammation in rat ileum/jejunum preparations and the 
mechanisms of action. Using RT-PCR the expression of the ARs mRNA was determined and 
an interaction between the receptors and STW 5 as well as STW 6 was characterized. The 
results were confirmed by receptor binding experiments and pharmacological use of 
selective receptor antagonists.  
2. Materials and methods 
2.1 Animals  
All procedures used throughout this study were conducted according to the German 
Guidelines for Animal Care and approved by the Institutional Review Board of Animal Care 
Committee. 
Adult male Wistar rats (8-10 weeks old, 150-220 g body weight) were obtained from the 
Biomedical Centre, Medical Faculty, University of Leipzig, and were maintained at room 
temperature in a light (12 h light/12 h dark) controlled environment with food and water ad 
libitum. The rats were anaesthetized with CO2 and killed by decapitation. The abdomen was 
immediately opened; intestinal segments (ileum and distal part of the jejunum) of about 
15 cm were rapidly removed and placed in a dish containing aerated modified Krebs 
solution at 37 °C.  
2.2 Materials 
STW 5 contains Iberis amara totalis (STW 6) fresh plant extract and eight dried plants as drug 
extracts (Table 1).  
STW 5 and STW 6 were kindly provided by Steigerwald Arzneimittelwerk GmbH, 
Darmstadt, Germany, in form of ethanol-free lyophilisates (58.0 mg resp. 18.2 mg 
corresponding to 1 ml of the fluid extract). STW 5 and STW 6 were dissolved in water. The 
concentrations of STW 5 were used as described before (Hohenester et al., 2004). STW 6 was 
used in equivalent concentrations to its proportion in STW 5.  
ACh (1 M) was prepared as fresh 1:10 dilution from a 10 M stock solution. The final 
concentration in the organ baths was 1 mM. ACh (1 mM) was used as positive control. PSB-
1115 (1-propyl-8-p-sulfophenylxanthine) was synthesized at the PharmaCenter Bonn, 
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Department of Pharmaceutical Chemistry I, University of Bonn, Germany, according to 
previously described procedures (Kirfel et al., 1997; Müller et al., 1993; Yan and Müller, 
2004), and purified by preparative HPLC to obtain a purity of >98 %.  
 
Plant extract Drug-extract ratio ml/100ml 
Iberis amara totalis  (STW 6) 1:1.5-2.5 15 
Menthae piperitae folium 1:2.5-3.5 5 
Matricariae flos 1:2.0-4.0 20 
Liquiritiae radix 1:2.5-3.5 10 
Angelicae radix 1:2.5-3.5 10 
Carvi fructus 1:2.5-3.5 10 
Silybi mariani fructus 1:2.5-3.5 10 
Melissae folium 1:2.5-3.5 10 
Chelidonii herba 1:2.5-3.5 10 
Table 1. Constituents of STW 5 
The modified Krebs solution contained (mM): NaCl (130.5), KCl (4.86), MgCl2 (1.2), 
NaH2PO4 (1.97), Na2HPO4 (4.63), CaCl2 (2.4) and glucose (11.4). The pH value was adjusted 
to 7.3. The reverse transcription (RT)-buffer contained 250 mM tris-HCl (pH 8.3 at 25 °C), 
250 mM KCl, 20 mM MgCl2 and 50 mM DTT. Phosphate buffered saline (PBS) contained 
(mM): NaCl (15.0), NaH2PO4 (4.0), Na2HPO4 (1.0) adjusted to a pH of 7.4. Tris-HCl was 
obtained from Carl Roth GmbH & Co KG, Karlsruhe, Germany. 
The RNA preparation kit was from Qiagen GmbH. Primers were from Invitrogen. Enzymes 
used for reverse transcription were from Fermentas GmbH. The PCR reaction kit was from 
Bio-Rad Laboratories GmbH, Munich, Germany. All other substances were purchased from 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
2.3 Radioligand binding assays 
The radioligand binding assays were performed according to methods established by Klotz 
and Muller (Klotz et al., 1989; Muller, 2000; Muller et al., 2002). All studies were carried out 
as competition assays.  
A1R was taken from rat cortical tissue homogenates. Boards with 48 or 96 cavities were 
used. Each cavity carried 30 µg proteins in 200 µl final volume. 2-Chloro-N6-
[3H]cyclopentyladenosine ([3H]CCPA, specific activity 42.6 Ci/mmol, KD 0.2 nM) was used 
as standard A1R agonist in a final concentration of 1 nM. Tris-HCl was used as medium. 
Unspecific binding was determined with complete displacement by adenosine deaminase 
resistant adenosine analogue 2-chloroadenosine (CADO 10 µM). The extracts were dissolved 
in water. Incubation of boards took place at room temperature for 1.5 h. After that all 
samples were filtered on a cell harvester (Brandel) with ice-cold tris-HCl and filled into 
scintillation tubes. After addition of 40 µl ultima gold cocktail (Perkin Elmer) for the 
amplification of [3H] signal the radiation intensity was measured in a LS counter (Packard). 
A2AR was taken from rat brain striatal tissue homogenates. Boards with 48 or 96 cavities were 
used. Each cavity carried 50 µg protein in 200 µl final volume. [3H]CGS 21680 (specific activity 
41 Ci/mmol, KD 15.5 nM) was used as standard A2AR agonist in a final concentration of 5 nM. 
Tris-HCl was used as medium. Unspecific binding was determined with complete 
displacement by broad spectrum AR agonist 5'-N-ethylcarboxamidoadenosine (NECA 50 µM). 
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The extracts were dissolved in water. Incubation of boards took place at room temperature for 
1.5 h. The final procedure was the same as for A1R preparations. 
The results were analyzed and displayed with GraphPad PRISM®.  
2.4 Induction of inflammation and drug application 
Inflammation was induced as previously described (Michael et al., 2009). In brief, an 
ileum/jejunum preparation approximately 10 cm long was prepared, cleaned and divided 
into four segments. One end of each segment was tied up with a thread and in the other end 
a canula was inserted through which TNBS (0.01 M) and/or test substances were instilled. 
Thereafter the canula was removed, and the end was closed with a thread. The preparation 
was suspended for 30 min in a 10 ml incubation chamber containing aerated modified Krebs 
solution. After preincubation the threads were removed and the preparation was rinsed 
with modified Krebs solution. Sections of 1.5 cm in length were prepared for the 
experiments. 
Four preparations per animal were used to test the effects of STW 5 and STW 6 in the same 
experiment. All experiments were repeated using at least three animals. Modified Krebs 
solution (control), TNBS (0.01 M) alone, or TNBS together with STW 5 (512 µg/ml) and 
STW 6 (24.1 µg/ml) respectively were instilled and incubated for 30 min.  
2.5 Recording of mechanical activity 
The preparations were suspended in 20 ml organ baths containing oxygenated (95 % O2,  
5 % CO2) modified Krebs solution maintained at 37 oC. Then they were attached to fixed 
pins in the bath and to isometric transducers (TSE Systems, Bad Homburg) using polyester 
threads. The preparations were allowed to equilibrate for 40 min under a tension of 10 mN 
interrupted by a wash out before starting the experiment. ACh (1 mM) was applied at the 
beginning of each experiment to test the sensitivity of the preparations. Thereafter ACh was 
applied into the organ bath every 20 min. A washout and equilibration period followed after 
registration of the maximum contraction. 
The ACh-evoked contraction was defined as difference between the basal tone and the first 
maximum contraction after drug application. For each experiment an untreated preparations 
(control 100%) and TNBS-treated preparation were used from the same animal. The TNBS-
induced alterations of ACh-induced contractions differed strongly between several 
experimental series. To evaluate the experimental series the damage was calculated as an 
internal standardisation of the TNBS-induced alterations of the ACh-contractions. 100% 
damage represents the effect of TNBS on ACh-contractions under control conditions.  
2.6 Van Gieson staining and morphometric analysis  
The middle part (0.5 cm) of each preparation was fixed in phosphate buffered 
paraformaldehyde (4 %), washed with PBS, dehydrated in sequential ethanol baths with 
increasing concentrations of ethanol (50 % to 99.8 %) and embedded in paraffin wax. Slices 
of 7 µm were cut with a Jung Biocut microtome (Leica). The slices were dewaxed with 
xylene and rehydrated in three sequential ethanol baths with decreasing concentrations that 
ranged from 99.8 % to 70 % ethanol. For histological studies, the sections were stained with 
haemalaun solution (Mayer, cell nuclei) and van Gieson solution (picric acid with sour 
fuchsine) according to the method of Romeis (Mikroskopische Technik, 1989). The slides 
were examined qualitatively under a light microscope at 20x magnification. For analysing of 
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the histological photographs the method of calibrated ocular micrometer gauge was used. 
Largest and smallest diameters of the tissue layers were determined to calculate the area of 
mucosa as well as muscularis (longitudinal and circular muscle layers). Three positions 
were implemented in the calculation. Ten objects from at least three animals were used for 
statistics. 
2.7 RNA isolation and reverse transcription 
Following the manufacturers protocol total RNA from ileum/jejunum segments was 
extracted after preincubation for 3 h using the RNeasy Mini kit® (Qiagen). 10 µl of the RNA 
eluates were activated with 1 µl of oligo-dT (20) 500 µg primers in a 5 min incubation step at 
70 °C in the Crocodile III cycler.  Reverse transcription was performed with 200 units of 
RevertAID (Fermentas) and dNTP (1 mM) in the Crocodile III cycler in the RT-buffer. The 
final volume was 20 µl.  The reaction was stopped by heating at 70 oC for 10 min. 
2.8 Real-time fluorescence PCR  
AR mRNA expression as well as the expression of TNFα and IL-10 mRNA were measured 
quantitatively by a ready-to-use real-time fluorescence polymerase chain reaction (PCR) 
assay. SYBR Green® Mix reaction (BioRad) was used in a MyIQ® cycler (BioRad) according 
to manufacturers protocol. β-actine was used as a housekeeping gene. The primers for β-
actin and the adenosine A1R were self-designed, whereas the primers for the A2AR, TNFα 
and IL-10 were found in literature (Chen et al. 2004). Table 2 summarizes the sequences of 
the primers.  
 
primer sequence origin 
ß-Actin sense 5’-TGTCACCAACTGGGACGATA-3’ designed by the 
authors ß-Actin antisense 5’-GGGGTGTTGAAGGTCTCAAA-3’ 
A1 sense 5’- CTGCTCCTCATGGTCCTCAT-3’ designed by the 
authors A1 antisense 5’- GGGCAGAAGAGGGTGATACA-3’ 
A2A sense 5’- CTCACGCAGAGTTCCATCTT-3’ 
Chen, 2004 
A2A antisense 5’- TCCATCTGCTTCAGCTGTCT-3’ 
TNFα sense 5’-TCAGCCTCTTCTCATTCCTG-3’ designed by the 
authors TNFα antisense 5’-GGCTACGGGCTTGTCACTCG-3’ 
IL-10 sense 5’- TTTAAGGGTTACTTGGGTTGC-3’ Klingenberg, 
2006 IL-10 antisense 5’- GCTCCACTGCCTTGCTTTTA-3’ 
Table 2. Primers for RT-PCR. 
Each sample contained 10 µl of the SYBR Green® SuperMix, 1 µl sense primer, 1 µl antisense 
primer, 1 µl complementary DNA and 7 µl sterile water in a volume of 20 µl. The results 
were analyzed using the ∆∆ct-method (Pfaffl et al., 2002) and expressed as relative gene 
expression.  
2.9 Maceration 
STW 6 (24.2 µg/ml) was extracted three times each with hexane, chloroform and ethyl 
acetate (water saturated). Emulsions were centrifuged. The solvent phase was siphoned off. 
The solvent phases of the three extractions of each solvent were combined and vacuum 
evaporated. The fractions as well as the remaining aqueous fraction were lyophilised. The 
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lyophylisates were analysed qualitatively by thin layer chromatography using standard 
protocols (Wagner, 1996) and quantitatively by high pressure liquid chromatography 
(HPLC, Kroll, 2006). The results of HPLC are shown in table 3. 
 
fraction Cucurbitacin E Cucurbitacin I mass percentage 
STW 6 44.4 µg/ml 31.6 µg/ml 100 % 
STW 6-CHCl3 31.4 µg/ml 14.9 µg/ml 3.2 % 
STW 6-EA 1.2 µg/ml 0.65 µg/ml 2.1 % 
STW 6-H2O n.d. n.d. 93.5 % 
Table 3. Quantitative results of the fraction chromatography (n.d. not detected). 
2.10 Statistics 
Experimental data are presented as the means±SEM of the number (n) of experiments. 
Multiple comparisons with a control value were performed by one-way analysis of variance 
followed by Student´s t-test. A probability level of 0.05 or less was considered statistically 
significant. Ki values were calculated by nonlinear correlation. 
3. Results 
3.1 Effects of STW 5 and STW 6 on ACh-contractions in inflamed preparations 
The ileum/jejunum preparations were pre-incubated with TNBS for 30 min. During this 
time a marked inflammation developed, manifested by a constant inhibition of the ACh-
induced contractions. As shown previously TNBS (1 mM - 1 M) resulted in a 
concentration-dependent inhibition of ACh-induced contractions (damage) with an IC50 
value of 63 mM. 100 mM TNBS reduced the ACh-induced contraction to approximately 
35 % in comparison to intact preparation of the same animal (Michael et al., 2010). The 
combined preincubation of the ileum/jejunum preparation with TNBS (0.01 M, 30 min) 
and STW 5 (64-512 µg/ml) or STW 6 in equivalent concentrations (3-24.1 µg/ml) 
diminished concentration-dependently the TNBS-induced damage of the ACh-
contraction. STW 5 (128-512 µg/ml) prevented up to 30 % of the TNBS-induced damage, 
whereas STW 6 at the highest concentration of 24.1 µg/ml had even a stronger effect of 
56.8±6.6 % (Fig. 1A).  
To study whether the TNBS-induced damage is linked with morphological alterations van 
Gieson staining was done followed by detailed morphometric analysis. Histological 
assessment revealed tissue damages in preparations pre-incubated with TNBS. As seen in 
Fig. 1 B, the mucosal area of control preparations was 22,150±100 µm2. It was reduced to 
16,080±810 µm2 by TNBS (0.1 M). The combined pre-incubation with TNBS and STW 5 
(29,980±2,150 µm2) or STW 6 (20,690±1,010 µm2) preserved the mucosa. The gradual 
reduction of the muscularis area (longitudinal and circular muscle layers) was even greater 
after TNBS incubation. The decrease was from 5,770±300 µm2 to 2,750±140 µm2.  STW 5 and 
STW 6 also prevented this TNBS-induced morphological disturbance (5,530±450 µm2 and 
5590±360 µm2, Fig. 1C). 
3.2 Effects of STW 5 and STW 6 on the gene expression of TNFα and IL-10  
Human monocyte is an established model to study the inflammatory or anti-inflammatory 
drugs (Linden, 2006; Sitkovsky et al., 2004). In previous studies we have shown that 
treatment of monocytes with STW 5 (128 µg/ml) or STW 6 (6.0 µg/ml) had no effect on the 
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TNFα release whereas LPS, a well described inflammatory mediator, stimulated the release 
of TNFα  from 0.007±0.007 ng/ml to 1.4±0.1 ng/ml. STW 5 prevented the LPS-induced 
TNFα release by depressing the release to 0.4±0.2 ng/ml. No inhibitory effect was found 
with STW 6 (Michael et al., 2009).  
 
                                     A 
 
B C 
 
Fig. 1. Effects of STW 5 and STW 6 on TNBS-induced damage of ACh-induced contractions 
in ileum/jejunum preparations. (A) Concentration response curves of the effect of STW 5 
(64-512 µg/ml) and STW 6 in equivalent concentrations (3-24 µg/ml) after coincubation with 
TNBS (0.01 M, 30 min). STW 5 and STW 6 prevented concentration dependently the TNBS-
induced damage. STW 6 at maximum concentration mediated a <20 % stronger effect than 
STW 5. Mean±SEM of nine experiments, *p<0.05, significant vs. control; +p<0.05 significant 
vs. previous value. Morphometric analysis of the effects of STW 5 and STW 6 on mucosa (B) 
and muscularis (C). STW 5 (512 µg/ml) and STW 6 (24.1 µg/ml) prevented the TNBS-
induced effects. Mean±SEM of 30 measurements (B and C), *p<0.05, significant vs. control; 
+p<0.05 significant vs. TNBS. 
www.intechopen.com
 
Inflammatory Bowel Disease – Advances in Pathogenesis and Management 
 
48
A 
 
B 
 
C 
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Fig. 2. Effects of TNBS alone and after coincubation of TNBS with STW 5 or STW 6 on TNFα 
and IL-10 gene expression in ileum/jejunum preparations. TNBS (0.01 M) increased 
significantly the TNFα gene expression. STW 5 (512 µg/ml, A) but not STW 6 (24.1 µg/ml, 
B) prevented the gene activation. The IL-10 gene expression was not affected significantly by 
TNBS (0.01 M). It was increased by coincubation of TNBS and STW 5 (512 µg/ml, C) and 
this effect was more pronounced with STW 6 (24.1 µg/ml, D). Mean±SEM of five 
experiments, * p<0.05 significant vs. control (blank column).  
Here, we investigated the gene expression of TNFα and additionally the gene expression of the 
anti-inflammatory cytokine IL-10. Preincubation of ileum/jejunum preparations with TNBS 
(0.01 M) resulted in a significant increase of the relative gene expression of TNFα by factor 
5.4±1.7 (Fig. 2A) and 4.5±1.1 (Fig. 2B) compared to the gene expression in control preparations. 
The combined preincubation with TNBS and STW 5 (512 µg/ml) reduced this factor to 2.7±0.9 
(Fig. 2A), whereas STW 6 had no significant effect (4.2±0.7) on the TNBS-increased gene 
expression (Fig. 2B). In contrast, TNBS did not influence the relative gene expression of IL-10 
(factor 0.86±0.50). After combined preincubation with STW 5 (512 µg/ml), the relative gene 
expression was significantly increased by factor 3.85±1.21 compared to the gene expression in 
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control preparations (Fig. 2C). The increase was even more pronounced after combined 
preincubation with STW 6 (24.1 µg/ml, factor 8.10±2.73, Fig. 2D).  
3.3 Gene expression and functionality of adenosine receptors 
RT-PCR was used to study the expression of receptor mRNA for A1R and A2AR in intact and 
TNBS-treated ileum/jejunum preparations.  
 
A 
 
B 
 
C 
 
D 
 
Fig. 3. Gene expression of A1R and A2AR as well as their alteration after incubation with TNBS 
and STW 5 (A and B). AR-mRNA expression was measured quantitatively by a ready-to-use 
real-time fluorescence polymerase chain reaction (PCR) assay and expressed as relative gene 
expression using the ∆∆ct-method. Effect of the A1R agonist CPA (10 µM) and the A1R 
antagonist DPCPX (0.1 µM) on the TNBS-induced decrease of the ACh (1 mM)  
-induced contractions (C). Effect of the A2AR agonist CGS 21680 (10 µM) and the A2AR 
antagonist CSC (0.2 µM) on TNBS-induced decrease of the ACh (1 mM) contractions (D). 
Mean±SEM of 12 experiments, *p<0,05 vs. control (open column), #p<0.05 vs. previous 
column.  
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A1R  and A2AR mRNA were identified in intact preparations. Incubation of the preparations 
with TNBS (10 mM,) resulted in a significant suppression of the mRNA expression. STW 5 
(512 µg/ml) coincubated with TNBS (10 mM) protected from TNBS-induced suppression of 
the A1R (Fig. 3A). The gene expression remained at control levels. For A2AR mRNA even a 
significant induction by factor 6.9±0.5 was detectable (Fig. 3B).  
The functionality of the adenosine A1R and A2AR was tested pharmacologically. 
Ileum/jejunum preparations were incubated with TNBS together with specific receptor 
agonists and antagonists for 30 min. After that ACh (1 mM)-induced contractions were 
recorded. TNBS (10 mM) decreased the ACh-induced contraction to 57.9±3.9 % (p<0.05 vs. 
control, n=12). After preincubation together with the A1R agonist CPA (10 µM), the decrease to 
38.8±3.26 % (n=12, p<0.05 vs. control). DPCPX (0.1 µM), described as inverse agonist on A1R, 
enhanced slightly the TNBS-reduced contractions but prevented the CPA-induced inhibition 
(65.0±5.1 %, p<0.05 vs. CPA, n=12, Fig. 3C). The activation of A2AR by CGS 21680 (10 µM) 
enhanced the TNBS-reduced contraction by 27 % (79.3±2.6 % vs. 52.3±2.1 %, p<0.05, n=9). The 
A2AR antagonist CSC (0.2 µM) had negligible effect on the TNBS-reduced contraction 
(52.3±2.6 % vs. 46.4±6.6 %, p>0.05, n=9), but it abolished completely the agonist-induced 
enhanced contraction (52.3±3.7 %, p<0.05 vs. CGS 21680, n=9, Fig. 3D).  
 
A B 
Fig. 4. Competition curves of STW 5 and STW 6 at the A1R and the A2AR. Displacement of 
(A) the radioactive labelled A1R agonist [3H]CCPA and (B) the radioactive labelled A2AR 
agonist [3H]CGS 21680. Half logarithmic line graphs of mean ± SEM of specific binding of 
[3H]CCPA and [3H]CGS 21680 from 3 independent experiments, respectively. A decreased 
binding of the radioactive labelled agonist represents competitive displacement by STW 5 or 
STW 6. The concentrations of STW 6 were calculated as equivalent to STW 5. Mean±SEM of 
three independent experiments. 
3.4 Receptor binding assays 
To evaluate an interaction between STW 5 and STW 6 and A1R and A2AR, receptor binding 
studies were designed. STW 5 and STW 6 were able to displace the radioactive labelled A1R 
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agonist [3H]CCPA (Fig. 4A) as well as radioactive labelled A2AR agonist [3H]CGS 21680 (Fig. 
4B) from these receptors in a concentration dependent manner. The shift of the displacement 
curve of STW 6 to the right indicates a very weak binding of this extract, which may be due 
to nonspecific interactions.   
3.5 Interaction of STW 5 and A2AR in inflamed preparations 
According to data from gene expression in further experiments the role of A1R and A2AR 
in STW 5 responses is indicative for an anti-inflammatory action and was therefore 
investigated in TNBS-treated ileum/jejunum preparations. STW 5 (512 µg/ml) was able to 
prevent the TNBS-induced damage of the ACh-contraction by 19.0 % (p<0.05 vs. control, 
n=18) in ileum/jejunum preparations. The A2AR antagonist CSC (0.2 µM) was 
significantly effective in blocking the effect of STW 5 (p<0.05, n=18, Fig. 5). The 
experiments were repeated in the presence of A1R antagonist DPCPX. The additional 
preincubation with DPCPX (0.1 µM) enhanced the damage of the ACh-induced 
contractions but did not affect the effective blockade by CSC (Fig. 5).The experiments 
indicate that the protective effect of STW 5 in TNBS-inflamed preparations is mediated 
primarily by activation of A2AR. 
 
 
Fig. 5. Impact of A2AR antagonist CSC and A1R antagonist DPCPX on the STW 5  
mediated effect on the TNBS-induced damage of the ACh contraction. STW 5  
(512 µg/ml) was incubated together with TNBS (0.01 M), CSC (0.2 µM) and  
DPCPX (0.1 µM,) or the combination of the antagonists. Means±SEM from 12 to 18 
experiments. *p<0.05 vs. TNBS (open column), # p<0.05 vs. previous column,  
+ p<0.05 vs. STW 5. 
3.6 Mechanism of action of STW 6 in inflamed preparations 
The experiments described above clearly indicate that the protective effect of STW 6 was 
not mediated by activation of A2AR or interaction with TNFα pathway rather than by 
activation of IL-10 pathway. Therefore, the next set of experiments was designed to study 
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the mechanisms involved in the action of STW 6. Bio-guided isolation of active 
ingredients within STW 6 was performed using solvents of different polarities.  
The hexane fraction had only a marginal mass portion (1.3 %) and was, therefore, 
excluded from further experiments. The chlorophorm, ethyl acetate and water fractions 
were concentrated to the equivalent concentration of STW 6 (24.1 µg/ml), respectively, and 
used for simultaneous incubation of ileum/jejunum preparations with TNBS. The 
chloroform (37.9±12.8%, p<0.05, n=9) and ethyl acetate fraction (29.7±9.9%, p<0.05,  
n=9), which contained the cucurtacines E and I (Fig. 6A), prevented the TNBS inhibition of 
the ACh-induced contractionsrespectively. The water fraction, devoid of cucurbitacins,  
was without effect. This observation was further supported by the fact that purified 
cucurbitacin E and I could antagonize the TNBS-induced damage of ACh- stimulated 
contraction with EC50 of 0.12 µM and 0.04 µM, respectively (Fig. 6B). Additionally, 
cucurbitacins were able to stimulate the IL-10 gene expression. TNBS was without effect 
on the relative IL-10 gene expression. Cucurbitacin E (10 mM) coincubated with TNBS 
(10 mM, 30 min) significantly induced IL-10 mRNA by the factor 7.0±2.8 (p<0.05 vs. 
control, n=3, Fig. 6C). 
4. Discussion 
Gastrointestinal inflammation is accompanied by structural and functional changes of the 
gut, leading to gastrointestinal motility disturbances during both acute and chronic 
inflammation (Collins, 1996). Motility disturbance may persist in the period following an 
episode of gastrointestinal inflammation, resulting in the development of IBS or functional 
dyspepsia, which are suggested to be part of a single syndrome (Holtmann et al., 1997). Both 
IBS and functional dyspepsia are associated with disturbed gastric motor function and 
decreased gastric emptying (Caballero-Plasencia et al., 1999). It is well established that 
inflammatory bowel diseases are chronic immune-mediated intestinal disorders. Both 
subtypes, Crohn’s disease (CD) and ulcerative colitis (UC), are considered to arise as a 
consequence of an aberrant intestinal immune response in genetically predisposed 
individuals (Xavier and Podolsky, 2007). In inflamed segments of the bowel, persistent 
overproduction of pro-inflammatory cytokines, such as TNFα and IL-6 and impaired 
production of anti-inflammatory cytokines are characteristic features (Strober and Fuss, 
2006). Furthermore, gut inflammation is associated with extensive structural and functional 
alterations of the enteric nervous system and dysregulation in neuroimmune interactions 
(Bischoff and Gebhardt, 2006). Different experimental animal models are used to address 
these clinical findings.  
In this study, using an in vitro inflammation model (Michael et al., 2009), we demonstrated 
that the action of STW 5 resulted in a reduction of TNBS-induced disturbance of 
contractions possibly by attenuation of the TNBS-induced morphological damages.  
The mechanism of action of STW 5 is based at least on two distinctive mechanisms. STW 5 
inhibited the pro-inflammatory TNFα pathway by activation of A2AR and STW 6,  
the fresh plant component of STW 5, stimulated the anti-inflammatory IL-10 pathway. It  
seems that cucurbitacins are involved in influencing this pathway. Both pathways 
effectively contribute to the overall effect of STW 5. It is known from numerous studies 
carried out with plant extracts that the whole extract has in most cases a better efficacy than 
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a single substance isolated from the extract (Wegener and Wagner, 2006). Our findings  
are in accordance with other pharmacological studies showing different effects of a single  
A 
 
B 
 
C 
Fig. 6. Effects of the fractions of STW 6 and the cucurbitacins E and I on the TNBS-induced 
damage and the influence of cucurbitacin E on IL-10 gene expression. (A) The chloroform 
and ethyl acetate fractions containing the cucurbitacins E and I but not the water faction 
without cucurbitacins antagonized the damage of the ACh-contraction. (B) cucurbitacin E 
and I coincubated wit TNBS reduced concentration dependently the TNBS-induced damage 
of the ACh contraction. (C) Cucurbitacine E coincubated with TNBS enhanced the IL-10 
gene expression. Means±SEM from 9 (A), 9 (B) and 3 (C) experiments. *p<0.05 significant vs. 
control. 
constituent of STW 5 on mechanisms which are discussed as underlying the manifestation of 
IBS (Heinle et al., 2006, Ammon et al., 2006). At present it is not understood in detail how this 
multi-target principle of STW 5 arises (Wagner, 2006; Wagner and Ulrich-Merzenich, 2009). 
TNFα is a pro-apoptotic cytokine, which is produced by a wide variety of cell types in 
response to various inflammatory stimuli. It promotes the pathogenesis of several health 
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disorders, in particular those related to ulcerative colitis and Crohn's disease. In both 
diseases there is an increased synthesis of pro-inflammatory cytokines, including TNFα and 
an influx of nonspecific inflammatory cells into the mucosa. The cytokines contribute to 
tissue damage either directly or indirectly (Heuschkel, 2000; Pallone and Monteleone, 2001). 
The main sources of TNFα in vivo are stimulated monocytes, fibroblasts, and endothelial 
cells. The signals triggering the TNFα secretion are not completely understood. LPS, the 
endotoxin of Gram-negative bacteria, stimulates in vitro these cells including cells of the 
monocytic lineage (Rietschel et al., 1996). Human monocytes are characterised by their high 
level production of TNFα and by their propensity to preferentially develop into potent 
dendritic cells. Therefore, the effect of STW 5 was not only determined on the gene 
expression in TNBS-pretreated tissue but also on the TNFα release from untreated and LPS-
stimulated human monocytes. Our data clearly show that TNBS increased the TNFα gene 
expression in rat intestinal tissue, which was reduced by STW 5. Additionally, STW 5 
inhibited the increased TNFα release in LPS-stimulated monocytes (Michael et al., 2009). 
These results point out that those inflammatory processes contribute to the damaged 
morphology and to the reduced contractility and provide evidence that the protective effect 
of STW 5 in TNBS-pretreated preparations is largely related to inflammatory processes. 
Interestingly, STW 6, the fresh plant component of STW 5, neither stimulated the gene 
expression nor the release of TNFα (Michael et al., 2011). On the other hand, STW 6 
enhanced drastically the gene expression of the anti-inflammatory cytokine IL-10 whereas 
STW 5 did it moderately. These results suggest that at least two different processes 
contribute to the protective effects of STW 5 in the gastrointestinal inflammation, and 
therefore, we focused to the mechanisms underlying the regulation of TNFα and IL-10. 
The purine nucleoside adenosine has been recognized for its regulatory functions in 
situations of cellular stress like ischemia, hypoxia and inflammation. The importance of 
agonists or antagonists of AR as modulators in the immune system is of great interest of the 
field of gastrointestinal inflammation (Estrela and Abraham, 2011). RT-PCR and 
immunohistochemical analysis demonstrated a wide distribution of AR in the 
neuromuscular compartment and mucosal/submucosal layers of both small and large 
intestine (Christofi et al., 2001; Puffinbarger et al., 1995). The protective effect of STW 5 
against inflammation in ileum/jejunum preparations is mainly mediated by activation of 
A2AR. Activation of A2AR by a selective agonist protects against TNBS-induced damage of 
the ACh-induced contractions and the results of binding studies clearly show an affinity of 
STW 5 to A2AR. In accordance with the present experiments the A2AR antagonist CSC was 
shown recently to be effective in blocking the STW 5-induced enhanced ACh contraction in 
inflamed rat small intestinal preparation (Michael et al., 2011). Although, STW 5 enhanced 
the gene expression of by A1R. The contribution of this receptor subtype could be excluded. 
STW 5 did not bind significantly to A1R and the activation of A1R by the selective agonist 
CPA enhanced the damage induced by TNBS.  
We found that both STW 5 and STW 6 protected from TNBS-induced damage but STW 6 did 
not interact with A2AR and therefore it did not inhibit the TNFα pathway. Others than this 
pathway must be involved. Based on recently published results we focused on the anti-
inflammatory cytokine IL-10. IL-10 was first identified as a cytokine, secreted by CD4+Th2-
cells, which inhibit cytokine production in antigen-presenting cells (Fiorentino et al., 1989). 
Its main function within the gastrointestinal tract is limitation and ultimately termination of 
immune responses. It acts as a key mediator for maintaining gut homeostasis (Paul et al., 
2011). IL-10 has long been known for its substantial role in regulating gut immunity, but its 
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contribution to inflammatory gut diseases was somewhat elusive. A recent study identified 
mutations in either IL-10 receptor subunits that are associated with early-onset enterocolitis, 
a severe phenotype of IBD. Other than genetic variants of IL-10 receptors, IL-10 and STAT3 
genes are also associated with IBD, emphasizing the involvement of the IL-10 signalling 
cascade in the pathogenesis of CD and UC. Interestingly, cucurbitacin E and I are inhibitors 
of STAT3. Cucurbitacin E inhibits tumor angiogenesis through VEGFR2-mediated Jak2-
STAT3 signaling pathway (Dong et al., 2010). Cucurbitacin I potently induces apoptosis in 
leukemia cell lines and in primary chronic lymphocytic leukemia cells and was associated 
with a reduction in serine 727 phosphorylation of STAT3 (Ishdorj et al., 2010). In our 
experiment the fractions of STW 6 containing cucurbitacin E and I prevented significantly 
the TNBS-mediated disturbance of the ACh-induced contraction. The involvement of the 
cucurbitacins was confirmed by coincubation of cucurbitacins with TNBS. Under these 
conditions the cucurbitacins reduced the TNBS-induced disturbance of the ACh-induced 
contractions in a concentration-dependent manner. Additionally, they increased 
significantly IL-10 mRNA. Therefore, it appears, that the induction of the anti-inflammatory 
cytokine IL-10 by cucurbitacins is a second mechanism underlying the protective action of 
STW 5 in our in vitro inflammation model. 
In conclusion, STW 5 exhibits significant anti-inflammatory properties which contribute to 
the reduction of TNBS-induced morphological and contractile changes. Its mode of action 
seems to be twofold: inhibition of the TNFα pathway by activation of A2AR and activation of 
the IL-10 pathway. These anti-inflammatory mechanisms appear to be involved in the multi-
target action of STW 5 as a new therapeutic approach in IBS. 
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